U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2Cl.Pt.2H3N
Molecular Weight 300.051
Optical Activity NONE
Additional Stereochemistry Yes
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0
Stereo Comments SP-4-2

SHOW SMILES / InChI
Structure of CISPLATIN

SMILES

N.N.[Cl-].[Cl-].[Pt++]

InChI

InChIKey=LXZZYRPGZAFOLE-UHFFFAOYSA-L
InChI=1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2

HIDE SMILES / InChI
Molecular Formula H3N
Molecular Weight 17.0305
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula Pt
Molecular Weight 195.084
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.drugbank.ca/drugs/DB00515 | https://www.ncbi.nlm.nih.gov/pubmed/27736024 | https://www.ncbi.nlm.nih.gov/pubmed/25159039

There is no available sources on the medical use of platinum iodide. The salt is insoluble.

CNS Activity

CNS Non-penetrant
1014
Curator's Comment: With the injection of cisplatin into mice 3 h after the LPS treatment, platinum was detected in the CCR during the 7 days after the injection, while platinum was not detected in the CCR of cisplatin-injected mice without LPS pretreatment and of mice simultaneous treated with cisplatin and LPS.

Originator

Approval Year

1978
87
Targets

Targets

Primary TargetPharmacologyConditionPotency
DNA
278
Target ID: CHEMBL2311221
Crosslinking Agent
81
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
CISPLATIN

Approved Use

Cisplatin injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin injection and cyclophosphamide. Cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin injection therapy. Advanced Bladder Cancer Cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy.

Launch Date

1978
Primary
Approved
8429
CISPLATIN

Approved Use

Cisplatin injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin injection and cyclophosphamide. Cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin injection therapy. Advanced Bladder Cancer Cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy.

Launch Date

1978
Primary
Approved
8429
CISPLATIN

Approved Use

Cisplatin injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin injection and cyclophosphamide. Cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin injection therapy. Advanced Bladder Cancer Cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy.

Launch Date

1978
Primary
Phase IV
63
CISPLATIN

Approved Use

Cisplatin injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin injection and cyclophosphamide. Cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin injection therapy. Advanced Bladder Cancer Cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy.

Launch Date

1978
PubMed

PubMed

TitleDatePubMed
Platinum-catalyzed one-pot alkenylation of aldehydes using alkynes and triethylsilane: dual catalysis by platinum(II) chloride.
2013 Nov 1
Synthesis of tetracyclic chromenones via platinum(II) chloride catalysed cascade cyclization of enediyne-enones.
2014 Feb 28
Retrospective Analysis of the Risk Factors for Grade IV Neutropenia in Oesophageal Cancer Patients Treated with a Docetaxel, Cisplatin, and 5-Fluorouracil Regimen.
2017
Patents

Patents

WO2017059434
4

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:18:53 GMT 2023
Edited
by admin
on Fri Dec 15 15:18:53 GMT 2023
Record UNII
Q20Q21Q62J
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CISPLATIN
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
USAN   INN  
Official Name English
CIS-DIAMMINEDICHLOROPLATINUM II
Common Name English
CISPLATIN [USAN]
Common Name English
CISPLATIN [USP-RS]
Common Name English
cisplatin [INN]
Common Name English
CIS-DIAMMINEDICHLOROPLATINUM [WHO-IP]
Common Name English
PEYRONE'S SALT
Common Name English
FAULDISCIPLA
Common Name English
CISPLATIN [MART.]
Common Name English
CISPLATIN [EP IMPURITY]
Common Name English
CISPLATINUM
WHO-IP LATIN  
Common Name English
PLATINOL
Brand Name English
CIS-DDP
Code English
NSC-119875
Code English
CISPLATIN [IARC]
Common Name English
CISPLATIN [EP MONOGRAPH]
Common Name English
(SP-4-2)-DIAMMINEDICHLOROPLATINUM [WHO-IP]
Common Name English
cis-Diamminedichloroplatinum
WHO-IP  
Common Name English
CISPLATIN [WHO-DD]
Common Name English
INT-230-6 COMPONENT CISPLATIN
Code English
INT230-6 COMPONENT CISPLATIN
Code English
LIPLACIS
Brand Name English
CISPLATIN [WHO-IP]
Common Name English
CISPLATIN [ORANGE BOOK]
Common Name English
CISPLATIN [USP MONOGRAPH]
Common Name English
CIS-PLATIN
Common Name English
CDDP
Common Name English
CISPLATIN [JAN]
Common Name English
CISPLATINUM [WHO-IP LATIN]
Common Name English
CISPLATIN [HSDB]
Common Name English
CISPLATIN [MI]
Common Name English
PLATINUM, DIAMMINEDICHLORO-, (SP-4-2)-
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C798
Created by admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
WHO-ATC L01XA01
Created by admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
FDA ORPHAN DRUG 238607
Created by admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
FDA ORPHAN DRUG 221906
Created by admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
WHO-VATC QL01XA01
Created by admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
NDF-RT N0000175413
Created by admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
FDA ORPHAN DRUG 134800
Created by admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
FDA ORPHAN DRUG 536616
Created by admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
FDA ORPHAN DRUG 447514
Created by admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
NDF-RT N0000175073
Created by admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
EU-Orphan Drug EU/3/13/1169
Created by admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
FDA ORPHAN DRUG 867921
Created by admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
LIVERTOX NBK548160
Created by admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
FDA ORPHAN DRUG 557716
Created by admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
NCI_THESAURUS C1450
Created by admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
FDA ORPHAN DRUG 783620
Created by admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
FDA ORPHAN DRUG 133200
Created by admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
Code System Code Type Description
MESH
D002945
Created by admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
PRIMARY
EPA CompTox
DTXSID4024983
Created by admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
PRIMARY
CAS
15663-27-1
Created by admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
PRIMARY
SMS_ID
100000088223
Created by admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
PRIMARY
ChEMBL
CHEMBL11359
Created by admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
PRIMARY
DRUG CENTRAL
4392
Created by admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
PRIMARY
NSC
119875
Created by admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
PRIMARY
NCI_THESAURUS
C376
Created by admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
PRIMARY
FDA UNII
Q20Q21Q62J
Created by admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
PRIMARY
PUBCHEM
84691
Created by admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
PRIMARY
LACTMED
Cisplatin
Created by admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
PRIMARY
HSDB
3939
Created by admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
PRIMARY
ECHA (EC/EINECS)
239-733-8
Created by admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
PRIMARY
IUPHAR
5343
Created by admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
PRIMARY
INN
4426
Created by admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
PRIMARY
CHEBI
27899
Created by admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
CISPLATIN
Created by admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
PRIMARY Description: White to yellowish crystals or a yellow powder.Solubility: Slightly soluble in water; sparingly soluble in dimethylformamide R; practically insoluble in methanol R.Category: Cytotoxic drug.Storage: Cisplatin should be kept in a tightly closed container, protected from light, and stored at a temperature between 2 and 8?C.Additional information: CAUTION: Cisplatin must be handled with care, avoiding contact with the skin and inhalation of airborneparticles.When heated, it blackens at about 270 ?C with decomposition.
WIKIPEDIA
CISPLATIN
Created by admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
PRIMARY
RS_ITEM_NUM
1134357
Created by admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
PRIMARY
DRUG BANK
DB00515
Created by admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
PRIMARY
MERCK INDEX
m3586
Created by admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
PRIMARY Merck Index
DAILYMED
Q20Q21Q62J
Created by admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
PRIMARY
RXCUI
2555
Created by admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
PRIMARY RxNorm
EVMPD
SUB07483MIG
Created by admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
PRIMARY
Related Record Type Details
MRP-1
TRANSPORTER -> SUBSTRATE
MRP-3
TRANSPORTER -> SUBSTRATE
MRP-2
TRANSPORTER -> SUBSTRATE
MULTIDRUG RESISTANCE PROTEIN 1
TRANSPORTER -> SUBSTRATE
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Related Record Type Details
Structure of MONOHYDROXYCISPLATIN
METABOLITE ACTIVE -> PRODRUG
OCCURS INTRACELLULARLY
Structure of PLATINATE(4-), DIAMMINEDICHLOROBIS(N-PHOSPHONOCARBAMATO(3-)-.KAPPA.O)-, HYDROGEN (1:4), (OC-6-33)-
PRODRUG -> METABOLITE ACTIVE
Structure of MONOAQUACISPLATINUM
METABOLITE ACTIVE -> PRODRUG
OCCURS INTRACELLULARLY
Related Record Type Details
Structure of CARBOPLATIN
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of TRANSPLATIN
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of TRICHLOROAMMINEPLATINATE
IMPURITY -> PARENT
ASSAY (HPLC)
Related Record Type Details
Structure of CISPLATIN
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966